A FACILE AND CONVENIENT SYNTHETIC METHOD FOR FLUORINE-CONTAINING 1,2-DIHYDROPYRIDO-[3,2-h]QUINAZOLINES AND PYRIDO[3,2-h]QUINAZOLINES

Etsuji Okada* and Norikado Tsukushi

Department of Chemical Science and Engineering, Faculty of Engineering, Kobe University, Kobe 657-8501, Japan

Abstract - 5,7-Bis(trifluoroacetyl)-8-quinolylamine (1) reacted with various aliphatic and aromatic aldehydes in the presence of aqueous ammonia to afford fluorine-containing 1,2-dihydropyrido[3,2-h]quinazolines (2) and pyrido[3,2-h]quinazoline-6-methanols (3) in moderate to high yields. Dehydrogenation of 2 with DDQ gave the corresponding pyrido-[3,2-h]quinazolines (4) in excellent yields. Conversion of alcohols (3) into hydrates (4) with DDQ was also successful.

In recent years, considerable attention has been focused on the development of new methodologies for the syntheses of many kinds of fluorine-containing heterocycles, since these compounds are now widely recognized as important organic materials showing interesting biological activities for their potential use in medicinal and agricultural scientific fields.¹ Previously we found that N,N-dimethyl-2,4-bis(trifluoro-acetyl)-1-naphthylamine undergoes a novel aromatic nucleophilic substitution with various amines, thiols and alcohols to give the corresponding N-N, N-S and N-O exchanged 2,4-bis(trifluoroacetyl)-1-naphthyl-amines, sulfides and ethers in excellent yields, respectively.² Up-to-dately we succeeded in extending the present S_NAr reaction to less reactive N,N-dimethyl-2-trifluoroacetyl-4-halo-1-naphthylamines.³ Later, we carried out applying this type of aromatic nucleophilic substitution and related reactions to the simple syntheses of naphthalene-fused heterocycles bearing trifluoromethyl groups.⁴ Besides, quinoline derivatives constitute an important class of heterocyclic compounds and the skeleton is found in a great

number of natural products, for example alkaloids showing interesting biological activities.⁵ Therefore, we have recently reported that N, N-dimethyl-5,7-bis(trifluoroacetyl)-8-quinolylamine reacts easily with various amines to give the corresponding 5,7-bis(trifluoroacetyl)-8-quinolylamines and its application to the synthesis of fluorine-containing 1*H*-pyrrolo[3,2-*h*]quinolines.⁶ As a part of our systematic research program on the simple syntheses of CF₃-containing heterocycles, we attempted to utilize 5,7-bis-(trifluoroacetyl)-8-quinolylamine (1) as a new and convenient building block for construction of quinoline-fused heterocycles bearing trifluoromethyl group and found that the title compounds (2 - 4) can be very easily synthesized by the reaction of 1 with aldehydes providing the C-2 unit and ammonia used as the N-3 source of the ring. These fluorine-containing pyridoquinazolines (2 - 4) are expected to show interesting pharmacological properties as antifungal agents⁷ and dopamine receptor agonists.⁸



Table 1. Reaction of 1 with Aldehydes (RCHO) in the Presence of Aqueous Ammonia^{a)}

Entry	R	RCHO equiv.	Time (h)	Product	Yield (%) ^{b)}
1	Me	3	6	2a	30 ^{c)}
2	Et	3	24	2b	62
3	<i>i</i> -Pr	5	72	2c	87
4	<i>p</i> -MeOC ₆ H₄	5	24	2d	84 (6)
5	<i>p</i> -MeOC ₆ H ₄	5	48	2d/3d	71/23
6	<i>p</i> -MeC ₆ H₄	5	24	2e	86 (5)
7	<i>p</i> -MeC ₆ H₄	5	48	2e/3e	71/21
8	C_6H_5	5	24	2f	88 (9)
9	C_6H_5	5	48	2f/3f	71/18
10	p-CIC ₆ H ₄	5	24	2g	60 (39)
11	p-CIC ₆ H ₄	5	96	2g/3g	50/46

a) Molar ratio, $[1]/[NH_3]=1/3$ for Entries 1 and 2; 1/5 for Entries 3-11. b) Isolated yields. Values in parentheses are the recovery of substrate (1). c) With 62 wt% yield of decomposition products.

The results are shown in Scheme 1 and summarized in Table 1. Reaction of 16 with aliphatic aldehydes such as propion- and isobutyraldehydes in the presence of ammonia proceeded readily under mild conditions to afford the corresponding 2-alkyl-6-trifluoroacetyl-4-trifluoromethyl-1,2-dihydropyrido[3,2-h]quinazolines (**2b**, **c**) in 62-87% yields. In the case of acetaldehyde, the desired 2-methyl derivative (**2a**) was isolated in 30% yield, though accompanied by 62 wt% of decomposition products. Unfortunately, attempted reactions in order to synthesize 2-unsubstituted derivative from 1, formaldehyde (formalin) and ammonia were unsuccessful. At 50 °C for 24 h, such aromatic aldehydes as *p*-substituted benzaldehydes reacted with 1 and aqueous ammonia to afford 2-aryl-1,2-dihydropyridoquinazolines (**2d-g**) in 60-88% yields, together with the recovery of unreacted substrate (1). Interestingly, in contrast to the cases of aliphatic aldehydes mentioned above, prolonged heating (48 - 96 h) for completing the reactions resulted in giving not only the *expected* **2d-g** in 50-71% yields but also the *unexpected* 2-aryl- α ,4-bis(trifluoromethyl)pyrido[3,2-h]quinazoline-6-methanols (**3d-g**) in 18-46% yields. Separation of the **2** - **3** mixtures was easily effected by chromatography on a silica gel column.

Treatment of 1,2-dihydropyrido[3,2-*h*]quinazolines (**2a-g**) with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) at room temperature for 1 h caused smooth dehydrogenation to give fluorine-containing pyrido[3,2-*h*]quinazolines (**4a-g**) in 85-95% yields (Scheme 2). 6-Trifluoroacetyl group of pyrido[3,2-*h*]-



quinazolines (4) was found to exist as hydrate form and this phenomenon was not observed in benzo-[h]quinazoline system.⁴ⁱ Furthermore, alcohols (**3d-g**) were also converted effectively with DDQ into **4d**g in excellent yields.

The structure of all new compounds (2 - 4) were determined from their ¹H-NMR and IR spectra, together with elemental analyses.

Thus, the present synthetic method provides a facile and convenient access to pyrido[3,2-h]quinazolines

having both trifluoromethyl and trifluoroacetyl groups which are not easily obtained by other methods.

EXPERIMENTAL

All melting points were determined on an electrothermal digital melting point apparatus and are uncorrected. IR spectra were recorded on a Hitachi EPI-G3 spectrophotometer. ¹H-NMR spectra were obtained with JEOL PMX 60SI instrument using CDCl₃ as a solvent unless otherwise indicated. All chemical shifts are reported in ppm downfield from internal tetramethylsilane; coupling constants (J) are given in Hz. Elemental analyses were taken with a Yanaco CHN Corder MT-5 analyzer. Chromatographic separations were carried out on a silica gel column (Fuji Silysia Chemical BW-127ZH; 100-270 mesh). All reagents were obtained commercially and used without further purification. Final purification of all products for elemental analyses was done by recrystallization.

Reaction of 5,7-Bis(trifluoroacetyl)-8-quinolylamine (1) with Aldehyde in the Presence of Ammonia; General Procedure: To a solution of 16 (336 mg, 1 mmol) in MeCN (5 mL) was added the appropriate aldehyde (3 - 5 mmol) and aqueous ammonia (28 wt.%, 182 - 304 mg, 3 - 5 mmol). The mixture was stirred at 50 °C for 6 - 96 h, the solvent was removed under reduced pressure, and EtOAc (50 mL) was added to the residue. This solution was washed with H_2O (100 mL) and dried (Na₂SO₄). The solvent was evaporated and the crude product was chromatographed using hexane/EtOAc (4:1) for **2a-g** and hexane/EtOAc (9:1) for **3d-g** as elucnt.

2a: mp 120-121 °C (hexane); IR (KBr) 3350, 3260, 1684, 1648 cm⁻¹; ¹H-NMR 9.44 (dd, 1H, J=2, 9, H-7), 8.69 (dd, 1H, J=2, 4, H-9), 8.24 (br s, 1H, H-5), 7.57 (dd, 1H, J=4, 9, H-8), 7.11 (br s, 1H, NH), 5.85 (q, 1H, J=6, H-2), 1.73 (d, 3H, J=6, CH₃). Anal. Calcd for C₁₅H₉N₃OF₆: C, 49.87; H, 2.51; N, 11.63. Found: C, 50.06; H, 2.71; N, 11.44.

2b: mp 98-99 °C (hexane); JR (KBr) 3345, 1667, 1645 cm⁻¹; ¹H-NMR 9.46 (dd, 1H, J=2, 9, H-7), 8.72 (dd, 1H, J=2, 4, H-9), 8.27 (br s, 1H, H-5), 7.60 (dd, 1H, J=4, 9, H-8), 7.17 (br s, 1H, NH), 5.93-5.59 (m, 1H, H-2), 2.31-1.85 (m, 2H, CH₂), 1.37 (t, 3H, J=7, CH₃). Anal. Calcd for C₁₆H₁₁N₃OF₆: C, 51.21; H, 2.95; N, 11.20. Found: C, 51.28; H, 3.01; N, 11.07.

2c: mp 89-90 °C (hexane); IR (KBr) 3350, 1680, 1652 cm⁻¹; ¹H-NMR 9.47 (dd, 1H, J=2, 9, H-7), 8.72 (dd, 1H, J=2, 4, H-9), 8.25 (br s, 1H, H-5), 7.59 (dd, 1H, J=4, 9, H-8), 7.14 (br s, 1H, NH), 5.63 (d, 1H, J=4, H-2), 2.47-1.95 (m, 1H, CH), 1.13 (d, 6H, J=6, CH₃). Anal. Calcd for C₁₇H₁₃N₃OF₆: C, 52.45; H, 3.37; N, 10.79. Found: C, 52.49; H, 3.52; N, 10.60.

2d: mp 160-161 °C (hexane/EtOAc); IR (KBr) 3300, 1680, 1642 cm⁻¹; ¹H-NMR (CD₃CN/CDCl₃) 9.50 (dd, 1H, J=2, 9, H-7), 8.77 (dd, 1H, J=2, 4, H-9), 8.34 (br s, 1H, H-5), 7.92-7.32 (m, 4H, H-8, *p*-MeOC₆<u>H</u>₄, NH), 6.94 (d, 2H, J=9, *p*-MeOC₆<u>H</u>₄), 6.80 (br s, 1H, H-2), 3.81 (s, 3H, OCH₃). Anal. Calcd for $C_{21}H_{13}N_3O_2F_6$: C, 55.64; H, 2.89; N, 9.27. Found: C, 55.58; H, 2.90; N, 9.22.

2e: mp 149-150 °C (hexane/EtOAc); IR (KBr) 3310, 1683, 1646 cm⁻¹; ¹H-NMR (CD₃CN/CDCl₃) 9.53 (dd, 1H, J=2, 9, H-7), 8.80 (dd, 1H, J=2, 4, H-9), 8.36 (br s, 1H, H-5), 7.88-7.16 (m, 6H, H-8, *p*-MeC₆<u>H</u>₄, NH), 6.83 (br s, 1H, H-2), 2.38 (s, 3H, CH₃). Anal. Calcd for C₂₁H₁₃N₃OF₆: C, 57.67; H, 3.00; N, 9.61. Found: C, 57.56; H, 2.92; N, 9.62.

2f: mp 148-149 °C (hexane/EtOAc); IR (KBr) 3370-2940, 1692, 1652 cm⁻¹; ¹H-NMR 9.53 (dd, 1H, J=2, 9, H-7), 8.76 (dd, 1H, J=2, 4, H-9), 8.40 (br s, 1H, H-5), 7.76-7.21 (m, 7H, H-8, C₆H₅, NH), 6.80 (br s, 1H, H-2). Anal. Calcd for C₂₀H₁₁N₃OF₆: C, 56.75; H, 2.62; N, 9.93. Found: C, 56.63; H, 2.74; N, 9.97.

2g: mp 172-173 °C (hexane/EtOAc); IR (KBr) 3325, 1695, 1654 cm⁻¹; ¹H-NMR (CD₃CN/CDCl₃) 9.49 (dd, 1H, J=2, 9, H-7), 8.74 (dd, 1H, J=2, 4, H-9), 8.37 (br s, 1H, H-5), 7.75-7.31 (m, 6H, H-8, *p*-ClC₆<u>H</u>₄, NH), 6.76 (br s, 1H, H-2). Anal. Calcd for C₂₀H₁₀N₃OClF₆: C, 52.48; H, 2.20; N, 9.18. Found: C, 52.26; H, 2.51; N, 9.09.

3d: mp 190-191 °C (hexane/EtOAc); IR (KBr) 3385 cm⁻¹; ¹H-NMR 9.98-9.11 (br, 1H, OH), 9.41 (dd, 1H, J=2, 9, H-7), 8.87 (dd, 1H, J=2, 4, H-9), 8.16 (br s, 1H, H-5), 7.93 (d, 2H, J=9, *p*-MeOC₆<u>H</u>₄), 7.65 (dd, 1H, J=4, 9, H-8), 6.99 (d, 2H, J=9, *p*-MeOC₆<u>H</u>₄), 5.63 (q, 1H, J_{CF}=8, CHCF₃), 3.87 (s, 3H, OCH₃). Anal. Calcd for C₂₁H₁₃N₃O₂F₆: C, 55.64; H, 2.89; N, 9.27. Found: C, 55.89; H, 3.01; N, 8.90.

3e: mp 198-199 °C (hexane/EtOAc); IR (KBr) 3385 cm⁻¹; ¹H-NMR 9.89-9.03 (br, 1H, OH), 9.40 (dd, 1H, J=2, 9, H-7), 8.86 (dd, 1H, J=2, 4, H-9), 8.15 (br s, 1H, H-5), 7.85 (d, 2H, J=8, *p*-MeC₆<u>H</u>₄), 7.63 (dd, 1H, J=4, 9, H-8), 7.28 (d, 2H, J=8, *p*-MeC₆<u>H</u>₄), 5.62 (q, 1H, J_{CF}=8, CHCF₃), 2.43 (s, 3H, CH₃). Anal. Calcd for C₂₁H₁₃N₃OF₆: C, 57.67; H, 3.00; N, 9.61. Found: C, 57.70; H, 2.96; N, 9.64. **3f:** mp 196-197 °C (hexane/EtOAc); IR (KBr) 3390 cm⁻¹; ¹H-NMR 9.88-9.31 (br, 1H, OH), 9.44 (dd, 1H, J=2, 9, H-7), 8.91 (dd, 1H, J=2, 4, H-9), 8.28-7.42 (m, 7H, H-5, H-8, C₆H₅), 5.69 (q, 1H, J_{CF}=8, CHCF₃). Anal. Calcd for C₂₀H₁₁N₃OF₆: C, 56.75; H, 2.62; N, 9.93. Found: C, 56.62; H,

2475

2.63; N, 9.93.

3g: mp 164-165 °C (hexane/EtOAc); IR (KBr) 3365 cm⁻¹; ¹H-NMR 9.90-9.28 (br, 1H, OH), 9.45 (dd, 1H, J=2, 9, H-7), 8.93 (dd, 1H, J=2, 4, H-9), 8.20 (br s, 1H, H-5), 7.96 (d, 2H, J=9, *p*-ClC₆<u>H</u>₄), 7.70 (dd, 1H, J=4, 9, H-8), 7.50 (d, 2H, J=9, *p*-ClC₆<u>H</u>₄), 5.68 (q, 1H, J_{CF}=8, CHCF₃). Anal. Calcd for C₂₀H₁₀N₃OClF₆: C, 52.48; H, 2.20; N, 9.18. Found: C, 52.40; H, 2.58; N, 9.20.

Dehydrogenation of 1,2-Dihydropyrido[3,2-*h*]quinazolines (2a-g) and Pyrido[3,2*h*]quinazoline-6-methanols (3d-g) with DDQ; General Procedure:

from 1,2-Dihydropyrido[3,2-h]quinazolines (2a-g): To a solution of 2a-g (1 mmol) in MeCN (16 mL) was added DDQ (227 mg, 1 mmol) and the solution was stirred at rt for 1 h (to 2a-g) or 2 h (to 3d-g). The insoluble matter was separated from the solution by filtration and washed with EtOAc (50 mL). The filtrate was washed once with saturated Na₂CO₃ (100 mL), once with H₂O (100 mL), and subsequently dried (Na₂SO₄). The solvent was evaporated to give the practically pure products (4a-g).

4a: yield 95%; mp 157 °C (decomp); IR (KBr) 3370-3110 cm⁻¹; ¹H-NMR (CD₃SOCD₃) 9.60-9.15 (m, 2H, H-7, H-9), 8.79-8.39 (m, 3H, H-5, OH), 7.98 (dd, 1H, J=4, 9, H-8), 3.06 (s, 3H, CH₃). Anal. Calcd for C₁₅H₉N₃O₂F₆: C, 47.76; H, 2.40; N, 11.14. Found: C, 47.83; H, 2.68; N, 10.79.
4b: yield 94%; mp 168-169 °C; IR (KBr) 3330 cm⁻¹; ¹H-NMR (CD₃SOCD₃) 9.50-9.13 (m, 2H, H-7, H-9), 8.73-8.34 (m, 3H, H-5, OH), 7.90 (dd, 1H, J=4, 9, H-8), 3.31 (q, 2H, J=8, CH₂), 1.50 (d, 6H, J=8, CH₃). Anal. Calcd for C₁₆H₁₁N₃O₂F₆: C, 49.12; H, 2.83; N, 10.74. Found: C, 48.97; H, 2.82; N, 10.45.

4c: yield 90%; mp 161-162 °C; IR (KBr) 3340 cm⁻¹; ¹H-NMR (CD₃SOCD₃) 9.63-9.24 (m, 2H, H-7, H-9), 8.90-8.42 (m, 3H, H-5, OH), 8.00 (dd, 1H, J=4, 9, H-8), 3.86-3.27 (m, 1H, CH), 1.55 (d, 6H, J=7, CH₃). Anal. Calcd for C₁₇H₁₃N₃O₂F₆: C, 50.38; H, 3.23; N, 10.37. Found: C, 50.31; H, 3.27; N, 10.40.

4d: yield 92% (from **2d**), 94% (from **3d**); mp 218-219 °C; IR (KBr) 3360-3110 cm⁻¹; ¹H-NMR (CD₃SOCD₃) 9.64-9.20 (m, 2H, H-7, H-9), 8.86-8.38 (m, 5H, H-5, *p*-MeOC₆<u>H₄</u>, OH), 7.97 (dd, 1H, J=4, 9, H-8), 7.17 (d, 2H, J=9, *p*-MeOC₆<u>H₄</u>), 3.90 (s, 3H, OCH₃). Anal. Calcd for C₂₁H₁₃N₃O₃F₆: C, 53.74; H, 2.79; N, 8.95. Found: C, 53.85; H, 3.02; N, 8.61.

4e: yield 91% (from **2e**), 90% (from **3e**); mp 200-201 °C; IR (KBr) 3360-3100 cm⁻¹; ¹H-NMR (CD₃SOCD₃) 9.57-9.14 (m, 2H, H-7, H-9), 8.82-8.33 (m, 5H, H-5, *p*-MeC₆<u>H</u>₄, OH), 7.92 (dd, 1H,

J=4, 9, H-8), 7.39 (d, 2H, J=9, p-MeC₆H₄), 2.42 (s, 3H, CH₃). Anal. Calcd for C₂₁H₁₃N₃O₂F₆: C, 55.64; H, 2.89; N, 9.27. Found: C, 55.79; H, 3.15; N, 8.86.

4f: yield 89% (from **2f**), 93% (from **3f**); mp 194-195 °C; IR (KBr) 3490 cm⁻¹; ¹H-NMR (CD₃SOCD₃) 9.64-9.24 (m, 2H, H-7, H-9), 8.94-8.40 (m, 5H, H-5, C₆H₅, OH), 8.15-7.48 (m, 4H, H-8, C₆H₅). Anal. Calcd for C₂₀H₁₁N₃O₂F₆: *C*, 54.68; H, 2.52; N, 9.57. Found: *C*, 54.54; H, 2.61; N, 9.61. **4g**: yield 85% (from **2g**), 82% (from **3g**); mp 191-192 °C; IR (KBr) 3370-3100 cm⁻¹; ¹H-NMR (CD₃SOCD₃) 9.68-9.25 (m, 2H, H-7, H-9), 8.85-8.43 (m, 5H, H-5, *p*-ClC₆H₄, OH), 8.00 (dd, 1H, J=4, 9, H-8), 7.65 (d, 2H, J=9, *p*-ClC₆H₄). Anal. Calcd for C₂₀H₁₀N₃O₂ClF₆: C, 50.70; H, 2.13; N, 8.87. Found: C, 50.72; H, 2.29; N, 8.69.

REFERENCES

- a) R. Filler, 'Organofluorine Chemicals and Their Industrial Applications,' ed. by R. E. Banks, Ellis Horwood, London, 1979; b) R. Filler and Y. Kobayashi, 'Biomedicinal Aspects of Fluorine Chemistry, 'Kodansha & Elsevier Biomedical, Tokyo, 1982; c) J. T. Welch, *Tetrahedron*, 1987, 43, 3123; d) R. Filler, Y. Kobayashi, and L. M. Yagupolskii, 'Organofluorine Compounds in Medicinal Chemistry and Biomedical Applications,' Elsevier, Amsterdam, 1993.
- a) M. Hojo, R. Masuda, and E. Okada, Tetrahedron Lett., 1987, 28, 6199; b) M. Hojo, R. Masuda,
 E. Okada, and H. Miya, Synthesis, 1989, 870; c) M. Hojo, R. Masuda, E. Okada, and H. Miya,
 Chem. Express, 1990, 5, 485; d) M. Hojo, R. Masuda, E. Okada, and H. Miya, Chem. Express,
 1990, 5, 569.
- 3. E. Okada, N. Tsukushi, Y. Otsuki, S. Nishiyama, and T. Fukuda, Synlett, 1999, 126.
- a) M. Hojo, R. Masuda, E. Okada, and H. Míya, Synthesis, 1989, 550; b) M. Hojo, R. Masuda, E. Okada, T. Tomifuji, and N. Imazaki, Synthesis, 1990, 1135; c) M. Hojo, R. Masuda, and E. Okada, Synthesis, 1990, 481; d) E. Okada, R. Masuda, M. Hojo, N. Imazaki, and K. Takahashi, Synthesis, 1992, 536; e) E. Okada, R. Masuda, M. Hojo, N. Imazaki, and H. Miya, Heterocycles, 1992, 34, 103; f) M. Hojo, R. Masuda, and E. Okada, Tetrahedron Lett., 1988, 29, 4599; g) E. Okada, R. Masuda, M. Hojo, and T. Tomifuji, Heterocycles, 1993, 36, 845; h) E. Okada, R. Masuda, M. Hojo, H. Tone, and T. Tomifuji, Heterocycles, 1994, 37, 157; i) E. Okada, R. Masuda, M. Hojo, H. Tone, N. Gotoh, and T. Huang, Heterocycles, 1995, 40, 905.

- a) R. P. Bahuguna, Y. C. Joshi, M. P. Dobhal, B. C. Joshi, and H. N. Mangal, *Heterocycles*, 1981, 16, 1955; b) R. P. Bahuguna and B. C. Joshi, *Indian J. Heterocycl. Chem.*, 1994, 3, 265; c) R. P. Bahuguna and B. C. Joshi, *Egypt. J. Chem.*, 1988, 31, 89; d) W. A. Denny, G. J. Atwell, and B. C. Baguley, *Anti-Cancer Drug Des.*, 1987, 2, 263; e) G. Jones, 'Quinolines,' ed. by G. Jones, Wiley-Interscience, London, 1977.
- 6. E. Okada and N. Tsukushi, Synlett, 1999, 210.
- J. H. Chan, J. S. Hong, L. F. Kuyper, M. L. Jones, D. P. Baccanari, R. L. Tansik, C. M. Boytos, S. K. Rudolph, and A. D. Brown, J. Heterocycl. Chem., 1997, 34, 145.
- a) R. A. Durham, J. D. Johnson, K. E. Moore, and K. J. Lookingland, *Brain Res.*, 1996, 732, 113; b) S. L. Gackenheimer, J. M. Schaus, and D. R. Gehlert, *J. Pharmacol. Exp. Ther.*, 1995, 273, 1558; c) R. Clement, D. Griff, B. Banks, C. Nemeroff, P. Kitabgi, and G. Bissette, *Synapse*, 1994, 17, 247.

Received, 15th June, 1999